Outcomes from second-line therapy in long-term responders to first-line tyrosine kinase inhibitor in clear-cell metastatic renal cell carcinoma

Reza Elaidi*, A. Harbaoui, B. Beuselinck, J. C. Eymard, A. Bamias, E. De Guillebon, C. Porta, Y. Vano, C. Linassier, P. R. Debruyne, M. Gross-Goupil, A. Ravaud, M. Aitelhaj, G. Marret, S. Oudard

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

In a comparison of tyrosine kinase inhibitor (TKI) and mammalian target of rapamycin inhibitor (mTORi) in patients with metastatic clear-cell renal cell carcinoma who received a 1st-line TKI for at least 6 months, the TKI-TKI sequence was favored over the TKI-mTORi. Long-term 2nd-line responders were more likely to have received a second TKI and to have been long-term responders to a 1st-line TKI.

Original languageEnglish
Pages (from-to)378-385
Number of pages8
JournalAnnals of Oncology
Volume26
Issue number2
DOIs
Publication statusPublished - 1 Feb 2015
Externally publishedYes

ASJC Scopus subject areas

  • Hematology
  • Oncology

Keywords

  • Kidney cancer
  • Mammalian target of rapamycin (mTOR)
  • Sequence
  • Tyrosine kinase inhibitor

Fingerprint

Dive into the research topics of 'Outcomes from second-line therapy in long-term responders to first-line tyrosine kinase inhibitor in clear-cell metastatic renal cell carcinoma'. Together they form a unique fingerprint.

Cite this